Pfizer offers a dividend yield of 6.24%, much higher than Johnson & Johnson's 2.07%, but Pfizer's payout is frozen and not fully covered by free cash flow, with rising debt and a recent $4.3 billion write-down signaling risk. Johnson & Johnson, despite a lower yield, has a strong dividend history with 64 consecutive annual raises, solid free cash flow coverage, and diversified product growth. Investors should watch Pfizer's upcoming prostate cancer drug data and Johnson & Johnson's December business review to gauge future prospects. Overall, Johnson & Johnson's dividend appears more reliable for income-focused investors due to its stability and growth potential.
As of Oct 08, 2026 18:11 WIB, Pfizer (PFE) trades at USD 27.98 with a dividend yield of 6.25%, slightly above the article's figure, and shows a minor 1-day price change of -0.07% on Pluang. Johnson & Johnson (JNJ) is priced at USD 257.26 with a dividend yield of 2.07%, matching the article, but its price dipped 0.46% in one day. Notably, Pfizer's market cap stands at $156.74 billion, much smaller than Johnson & Johnson's $622.84 billion, highlighting the size difference between these dividend-paying giants.
At the Veeva R&D and Quality Summit in Boston, leading biopharma companies like Eli Lilly, Pfizer, and Sanofi shared innovations in AI, cloud platforms, and connected trials to accelerate drug development and improve quality. Highlights include Eli L...
Six well-known dividend-paying companies, including Pfizer, Icahn Enterprises, and Western Union, have been distributing dividends exceeding their net income and operating cash flow for multiple years. This practice often relies on borrowing, which i...
Scotiabank has increased its price target for Pfizer stock from $30.00 to $33.00, suggesting a potential upside of 20.9% from the current trading price of $27.31. Pfizer, a major pharmaceutical company, holds a strong buy rating with a Zacks Rank of ...
Moderna's stock has soared 545% year-to-date, driven by its mRNA technology and a promising oncology pipeline including a personalized cancer vaccine. The company now joins the NASDAQ 100, increasing its visibility and institutional interest. Despite...
Vaccine stocks surged after a Siberian plague scare, but health officials have since declared the risk low, causing Novavax shares to drop 2% after a prior 20% spike. Novavax's rally was driven by speculation of government vaccine purchases, but the ...
